PC
IMVTW

Periscope Capital’s Immunovant, Inc. Warrants expiring 12/18/2024 IMVTW Stock Holding History

Periscope Capital’s Portfolio IMVTW Stock Details IMVTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-35,154
Closed -$70K – 261
2019
Q4 		$70K Buy
+35,154
New +$71.2K 0.01% 198

Other funds holding IMVTW

BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GL
Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Periscope Capital's IMVTW Position: Q1 2020 in Review

Periscope Capital sold out of Immunovant, Inc. Warrants expiring 12/18/2024 (IMVTW) in Q1 2020, closing a stake of 35,154 shares — an estimated $70K sold.

Periscope Capital first reported a position in IMVTW in Q4 2019 and held it in 1 quarter. The position peaked at $70K in Q4 2019. 17 funds tracked by Wall St. Rank hold IMVTW as of Q1 2020.

  • Periscope Capital reported no remaining Immunovant, Inc. Warrants expiring 12/18/2024 position as of Q1 2020 after selling out during the quarter.
  • Periscope Capital sold 35,154 Immunovant, Inc. Warrants expiring 12/18/2024 shares in Q1 2020, an estimated $70K.
  • Periscope Capital first reported a position in Immunovant, Inc. Warrants expiring 12/18/2024 in Q4 2019 and held it in 1 quarter.
  • Periscope Capital's Immunovant, Inc. Warrants expiring 12/18/2024 position peaked at $70K in Q4 2019.
  • 17 funds tracked by Wall St. Rank held Immunovant, Inc. Warrants expiring 12/18/2024 as of Q1 2020.

Based on Periscope Capital's 13F filing for Q1 2020, filed 14 May 2020.